≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Tuberous sclerosis 1

Endpoint Browser PheWeb

Q17_TUBEROUS_SCLEROSIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q85.1
  • Cause of death: ICD-10 — Q85.1

2 out of 7 registries used, show all original rules.

75

4. Check minimum number of events

None

75

5. Include endpoints

None

75

6. Filter based on genotype QC (FinnGen only)

69

Control definitions (FinnGen only)

Control exclude
Q17_OTHER_CONGEN_MALFO

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 69 45 24
Unadjusted period prevalence (%) 0.01 0.02 0.01
Median age at first event (years) 28.85 31.67 23.57

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
75
Matched controls
750
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q85.1
ICD-10 Finland
Tuberous sclerosis
+∞
107.8
75
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
37.8
53.8
40
22
Z31.5
ICD-10 Finland
Genetic counselling
22.6
39.9
37
31
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
19.5
38.7
42
46
Q85.00
ICD-10 Finland
Neurofibromatosis, type 1
+∞
32.7
29
*
Q85.01
ICD-10 Finland
Neurofibromatosis, type 2
+∞
26.6
24
*
Q85.09
ICD-10 Finland
Unspecified neurofibromatosis
+∞
23.1
21
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
7.8
18.0
38
87
N03AF02
ATC
oxcarbazepine; oral
26.4
17.5
24
13
G40.9
ICD-10 Finland
Epilepsy, unspecified
33.8
17.2
22
9
N03AG01
ATC
valproic acid; systemic, rectal
18.5
17.1
27
22
183
Kela drug reimbursment
Lamotrigin and topiramate
49.9
16.3
19
5
Q85.0
ICD-10 Finland
Neurofibromatosis (nonmalignant)
+∞
16.2
15
*
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
35.6
15.2
19
7
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
18.9
15.0
23
17
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
38.7
14.7
18
6
181
Kela drug reimbursment
Retigabine and vigabatrin
+∞
14.0
13
*
N03AG04
ATC
vigabatrin; oral
+∞
14.0
13
*
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
17.9
11.1
17
12
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
38.7
10.7
13
*
N05BA09
ATC
clobazam; oral
38.7
10.7
13
*
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
127.0
10.7
11
*
ZXC10
NOMESCO Finland
Use of laser
28.2
10.7
14
6
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
+∞
10.7
10
*
N03AX09
ATC
lamotrigine; oral
10.9
10.4
20
24
XA800
NOMESCO Finland
Neuropsychological investigation
6.7
10.3
19
36
N05CD08
ATC
midazolam; nasal, systemic
24.1
10.2
14
7
N05BA01
ATC
diazepam; systemic, rectal
6.5
10.2
20
40
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
63.5
9.9
11
*
D33.30
ICD-10 Finland
Acoustic neuroma
63.5
9.9
11
*
N03AX14
ATC
levetiracetam; systemic
13.4
9.9
17
16
XCK00
NOMESCO Finland
Perimetry
16.7
9.7
15
11
N03AF01
ATC
carbamazepine; oral, rectal
18.7
9.5
14
9
G40.10
ICD-10 Finland
Simple partial seizures
42.3
9.3
11
*
ZXE10
NOMESCO Finland
More than one and less than three hours
4.3
8.9
39
152
G40.4
ICD-10 Finland
Other generalized epilepsy and epileptic syndromes
100.9
8.6
9
*
KA1AE
NOMESCO Finland
Kidney ultrasound examination
20.0
8.4
12
7
N03AX11
ATC
topiramate; oral
15.4
8.2
13
10
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
12.0
7.9
14
14
WX002
NOMESCO Finland
Sedation and analgesia
4.9
7.9
21
55
7595A
ICD-9 Finland
Other and unspecified congenital anomalies, Tuberous sclerosis
+∞
7.4
7
*
340
Kela drug reimbursment
Everolimus
+∞
7.4
7
*
AA1AD
NOMESCO Finland
CT of head and brain
4.2
7.3
26
85
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
33.6
7.3
9
*
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
33.6
7.3
9
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.9
7.2
30
110
QDE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in lower limb
15.8
7.1
11
8
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
7.8
7.1
16
25
ZXE20
NOMESCO Finland
More than three and less than five hours
5.1
7.0
17
41
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
25.2
6.8
9
*
F70.0
ICD-10 Finland
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
25.2
6.8
9
*
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
25.2
6.8
9
*
ZXD10
NOMESCO Finland
Scheduled procedure
3.5
6.6
39
178
ZXC07
NOMESCO Finland
Carbon dioxide laser
76.0
6.5
7
*
D23.3
ICD-10 Finland
Benign neoplasm: Skin of other and unspecified parts of face
76.0
6.5
7
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
20.1
6.4
9
5
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
20.1
6.4
9
5
XCW99
NOMESCO Finland
Other investigative procedure of eye
6.1
6.4
17
34
ZXC12
NOMESCO Finland
Pulse colorlaser
+∞
6.3
6
*
Q85.9
ICD-10 Finland
Phakomatosis, unspecified
+∞
6.3
6
*
2377A
ICD-9 Finland
Neoplasm of uncertain behaviour of endocrine glands and nervous system, Neurofibromatosis
+∞
6.3
6
*
R56.8
ICD-10 Finland
Other and unspecified convulsions
6.5
6.3
16
30
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
14.2
6.3
10
8
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
9.3
6.1
12
15
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.2
6.1
19
56

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
1.8e+00
2.1e+00
—
1.0e+50
3.0e+00
2.7e+00
2.7e+00
cases:26.67%
controls:5.73%
cases:21.67%
controls:3.20%
—
—
cases:25.00%
controls:0.00%
cases:15.00%
controls:0.84%
cases:35.59%
controls:3.71%
cases:52.63%
controls:6.75%
16
34
44
559
13
19
47
574
—
15
0
45
593
9
5
51
588
21
22
38
571
30
39
27
539
Outpatient Visit
OP [9202]
1.1e+00
1.4e+00
1.3e+00
1.0e+50
1.7e+00
2.8e+00
2.4e+00
cases:78.33%
controls:55.14%
cases:73.33%
controls:39.46%
cases:25.00%
controls:8.60%
cases:75.00%
controls:0.00%
cases:35.00%
controls:9.27%
cases:91.53%
controls:39.63%
cases:96.49%
controls:71.45%
47
327
13
266
44
234
16
359
15
51
45
542
45
0
15
593
21
55
39
538
54
235
5
358
55
413
2
165
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.3e+00
2.8e+00
—
1.0e+50
—
2.2e+00
2.1e+00
cases:28.33%
controls:3.71%
cases:15.00%
controls:1.01%
—
—
cases:10.00%
controls:0.00%
—
—
cases:18.64%
controls:2.53%
cases:31.58%
controls:5.36%
17
22
43
571
9
6
51
587
—
6
0
54
593
—
11
15
48
578
18
31
39
547
Neurosurgery
14 [38004459]
2.8e+00
2.9e+00
—
1.0e+50
—
—
3.1e+00
cases:21.67%
controls:1.69%
cases:13.33%
controls:0.84%
—
—
cases:10.00%
controls:0.00%
—
—
—
—
cases:24.56%
controls:1.38%
13
10
47
583
8
5
52
588
—
6
0
54
593
—
—
14
8
43
570
oxcarbazepine; oral
N03AF02 [21604418]
—
2.6e+00
—
—
—
2.9e+00
3.2e+00
—
—
cases:10.00%
controls:0.84%
—
—
—
—
—
—
cases:13.56%
controls:0.84%
cases:17.54%
controls:0.87%
—
6
5
54
588
—
—
—
8
5
51
588
10
5
47
573
Ophthalmology
18 [38004463]
1.7e+00
1.6e+00
—
—
—
1.7e+00
1.2e+00
cases:40.00%
controls:10.79%
cases:23.33%
controls:5.90%
—
—
—
—
—
—
cases:32.20%
controls:8.09%
cases:36.84%
controls:14.36%
24
64
36
529
14
35
46
558
—
—
—
19
48
40
545
21
83
36
495
Outpatient Hospital
22 [8756]
9.8e-01
1.4e+00
—
—
—
1.6e+00
1.4e+00
cases:40.00%
controls:20.07%
cases:18.33%
controls:5.23%
—
—
—
—
—
—
cases:22.03%
controls:5.56%
cases:38.60%
controls:12.98%
24
119
36
474
11
31
49
562
—
—
—
13
33
46
560
22
75
35
503
Paediatric neurology
421 [44777781]
2.0e+00
2.7e+00
—
1.0e+50
—
1.9e+00
2.3e+00
cases:10.00%
controls:1.52%
cases:11.67%
controls:0.84%
—
—
cases:8.33%
controls:0.00%
—
—
cases:8.47%
controls:1.35%
cases:14.04%
controls:1.56%
6
9
54
584
7
5
53
588
—
5
0
55
593
—
5
8
54
585
8
9
49
569
Plastic And Reconstructive Surgery
24 [38004467]
1.3e+00
2.2e+00
—
—
—
—
2.3e+00
cases:8.33%
controls:2.53%
cases:10.00%
controls:1.18%
—
—
—
—
—
—
—
—
cases:14.04%
controls:1.56%
5
15
55
578
6
7
54
586
—
—
—
—
8
9
49
569
Scheduled procedure
ZXD10 [2001311387]
1.4e+00
2.2e+00
—
—
—
—
2.0e+00
cases:16.67%
controls:4.72%
cases:10.00%
controls:1.18%
—
—
—
—
—
—
—
—
cases:12.28%
controls:1.90%
10
28
50
565
6
7
54
586
—
—
—
—
7
11
50
567
Upper gastrointestinal surgery
106 [44777669]
—
—
—
—
—
2.3e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:11.86%
controls:1.35%
cases:24.56%
controls:4.67%
—
—
—
—
—
7
8
52
585
14
27
43
551
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
—
—
—
—
—
2.4e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:0.84%
cases:17.54%
controls:4.15%
—
—
—
—
—
5
5
54
588
10
24
47
554
Pathology report gross observation
24419-4 [3002256]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:0.87%
—
—
—
—
—
—
6
5
51
573
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:0.87%
—
—
—
—
—
—
6
5
51
573
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.28%
controls:1.04%
—
—
—
—
—
—
7
6
50
572
Inpatient Hospital
21 [8717]
3.9e-01
6.3e-01
-1.0e+50
—
2.0e+00
1.5e+00
1.0e+00
cases:40.00%
controls:31.03%
cases:15.00%
controls:8.60%
cases:0.00%
controls:1.01%
—
—
cases:8.33%
controls:1.18%
cases:32.20%
controls:9.27%
cases:40.35%
controls:19.55%
24
184
36
409
9
51
51
542
0
6
60
587
—
5
7
55
586
19
55
40
538
23
113
34
465
More than one and less than three hours
ZXE10 [2001311401]
1.2e+00
—
—
—
—
—
2.4e+00
cases:11.67%
controls:3.88%
—
—
—
—
—
—
—
—
—
—
cases:21.05%
controls:2.25%
7
23
53
570
—
—
—
—
—
12
13
45
565
Oncology Clinic/Center
261QX0200X [38004268]
1.8e+00
—
—
—
—
—
2.4e+00
cases:11.67%
controls:2.19%
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:1.04%
7
13
53
580
—
—
—
—
—
6
6
51
572
Examination and observation for other specified reasons
Z04.8 [45552063]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:0.87%
—
—
—
—
—
—
5
5
52
573
Sensorineural hearing loss, bilateral
H90.3 [45576850]
1.8e+00
—
—
—
—
—
2.3e+00
cases:10.00%
controls:1.85%
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:1.21%
6
11
54
582
—
—
—
—
—
6
7
51
571
fusidic acid; ointment
D06AX01 [21602062]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:17.54%
controls:2.42%
—
—
—
—
—
—
10
14
47
564
fusidic acid
D09AA02 [21602265]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:17.54%
controls:2.42%
—
—
—
—
—
—
10
14
47
564
Case Management Agency
251B00000X [38004193]
3.8e-01
2.9e-01
6.8e-01
2.1e+00
3.6e-01
4.3e-01
3.4e-01
cases:53.33%
controls:43.84%
cases:43.33%
controls:36.42%
cases:21.67%
controls:12.31%
cases:10.00%
controls:1.35%
cases:20.00%
controls:14.84%
cases:50.85%
controls:40.30%
cases:71.93%
controls:64.53%
32
260
28
333
26
216
34
377
13
73
47
520
6
8
54
585
12
88
48
505
30
239
29
354
41
373
16
205
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
2.1e+00
—
—
1.0e+50
—
1.0e+50
—
cases:10.00%
controls:1.35%
—
—
—
—
cases:8.33%
controls:0.00%
—
—
cases:15.25%
controls:0.00%
—
—
6
8
54
585
—
—
5
0
55
593
—
9
0
50
593
—
enoxaparin; parenteral
B01AB05 [21600976]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.28%
controls:1.73%
—
—
—
—
—
—
7
10
50
568
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
—
1.3e+00
—
—
—
1.9e+00
1.1e+00
—
—
cases:10.00%
controls:3.04%
—
—
—
—
—
—
cases:16.95%
controls:3.04%
cases:26.32%
controls:10.90%
—
6
18
54
575
—
—
—
10
18
49
575
15
63
42
515
Examination of eyes and vision
Z01.0 [45566391]
1.7e+00
1.8e+00
—
—
—
—
1.8e+00
cases:11.67%
controls:2.36%
cases:8.33%
controls:1.52%
—
—
—
—
—
—
—
—
cases:14.04%
controls:2.60%
7
14
53
579
5
9
55
584
—
—
—
—
8
15
49
563
pH of Serum or Plasma
2753-2 [3018418]
—
—
—
—
—
1.8e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:1.52%
cases:14.04%
controls:2.77%
—
—
—
—
—
5
9
54
584
8
16
49
562
Essential (primary) hypertension
I10 [45591453]
8.8e-01
—
—
—
—
1.7e+00
9.5e-01
cases:10.00%
controls:4.38%
—
—
—
—
—
—
—
—
cases:13.56%
controls:2.70%
cases:17.54%
controls:7.61%
6
26
54
567
—
—
—
—
8
16
51
577
10
44
47
534
Leukocytes [#/volume] in Urine
30405-5 [3018095]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:19.30%
controls:4.50%
—
—
—
—
—
—
11
26
46
552
Medical doctor
Z2221 [2001311556]
1.5e+00
—
—
—
—
—
1.5e+00
cases:16.67%
controls:4.22%
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:2.60%
10
25
50
568
—
—
—
—
—
6
15
51
563
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
—
—
—
—
—
1.8e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:1.85%
cases:17.54%
controls:4.67%
—
—
—
—
—
6
11
53
582
10
27
47
551
Tissue Pathology biopsy report
66121-5 [40768804]
—
—
—
—
—
-1.0e+50
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
cases:17.54%
controls:4.67%
—
—
—
—
—
0
10
59
583
10
27
47
551
Emergency Room Visit
ER [9203]
4.3e-01
9.8e-01
—
—
—
1.2e+00
7.3e-01
cases:40.00%
controls:30.35%
cases:20.00%
controls:8.60%
—
—
—
—
—
—
cases:25.42%
controls:9.27%
cases:43.86%
controls:27.34%
24
180
36
413
12
51
48
542
—
—
—
15
55
44
538
25
158
32
420
Office Visit
OMOP4822458 [581477]
2.6e-01
1.0e+00
—
—
—
1.0e+00
1.2e+00
cases:13.33%
controls:10.62%
cases:8.33%
controls:3.20%
—
—
—
—
—
—
cases:10.17%
controls:3.88%
cases:24.56%
controls:9.00%
8
63
52
530
5
19
55
574
—
—
—
6
23
53
570
14
52
43
526
Internal Medicine
11 [38004456]
1.1e+00
1.3e+00
—
—
—
1.2e+00
1.7e-01
cases:30.00%
controls:12.82%
cases:16.67%
controls:5.40%
—
—
—
—
—
—
cases:16.95%
controls:5.90%
cases:19.30%
controls:16.78%
18
76
42
517
10
32
50
561
—
—
—
10
35
49
558
11
97
46
481
Pharmacy visit
OMOP4822462 [581458]
9.4e-01
8.8e-01
9.5e-01
—
8.5e-01
8.8e-01
9.3e-01
cases:96.67%
controls:91.91%
cases:88.33%
controls:75.89%
cases:58.33%
controls:35.08%
—
—
cases:51.67%
controls:31.37%
cases:86.44%
controls:72.51%
cases:96.49%
controls:91.52%
58
545
2
48
53
450
7
143
35
208
25
385
—
31
186
29
407
51
430
8
163
55
529
2
49
Recurrent depression, moderate episode without somatic syndrome
F33.10 [2000501984]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
—
—
-1.0e+50
—
-1.0e+50
1.0e+00
5.4e-01
—
—
—
—
cases:0.00%
controls:0.84%
—
—
cases:0.00%
controls:1.01%
cases:8.47%
controls:3.20%
cases:14.04%
controls:8.65%
—
—
0
5
60
588
—
0
6
60
587
5
19
54
574
8
50
49
528
insulin lispro; parenteral
A10AB04 [21600718]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
0
5
60
588
—
—
Other disorders of vitreous body
H43.8 [45533329]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
betamethasone
D07AC01 [21602120]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
7
60
586
—
—
—
—
—
Restricted oral and dental health check by dental hygienist or dental assistant
SAB01 [2001310279]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
60
584
—
—
—
—
—
—
Pain in limb
M79.6 [45587063]
—
—
—
—
—
—
4.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:5.54%
—
—
—
—
—
—
5
32
52
546
propranolol; oral, parenteral
C07AA05 [21601670]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
0
15
60
578
—
—
—
—
0
7
59
586
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
—
—
—
—
—
—
7.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:4.50%
—
—
—
—
—
—
5
26
52
552
Hand/finger symptom/complaint
L12 [2002000636]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Insulin-dependent diabetes diabetic hypoglycemic coma
E10.00 [2000501424]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
0
5
60
588
—
—
—
—
—
0
8
57
570
Osmolality of Urine
2695-5 [3026782]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:1.90%
—
—
—
—
—
—
6
11
51
567
Emergency treatment
SGA01 [2001310379]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.08%
—
0
6
60
587
—
—
—
—
0
12
57
566
Polyp of corpus uteri
N84.0 [45596887]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Urology
34 [38004474]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.28%
controls:2.25%
—
—
—
—
—
—
7
13
50
565
cough suppressants and mucolytics
R05FB01 [21603441]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
hydrochlorothiazide; oral
C03AA03 [21601466]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
cases:0.00%
controls:1.52%
cases:0.00%
controls:2.42%
—
0
6
60
587
—
—
—
0
9
59
584
0
14
57
564
Left side
ZXA05 [2001311347]
1.5e+00
—
—
—
—
—
—
cases:10.00%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
—
—
6
14
54
579
—
—
—
—
—
—
Type 2 diabetes mellitus
E11 [45571656]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.19%
cases:0.00%
controls:0.84%
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
0
13
60
580
0
5
60
588
—
—
—
0
6
59
587
—
Basic examination of mouth
SAA02 [2001310275]
6.1e-01
—
—
—
-1.0e+50
6.2e-01
-2.9e-01
cases:16.67%
controls:9.78%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:10.17%
controls:5.73%
cases:19.30%
controls:24.22%
10
58
50
535
—
—
—
0
5
60
588
6
34
53
559
11
140
46
438
Body mass index
60621009 [4245997]
—
—
-1.0e+50
—
—
—
1.0e+50
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
cases:12.28%
controls:0.00%
—
—
0
6
60
587
—
—
—
7
0
50
578
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
—
—
—
—
—
9.6e-02
1.8e-01
—
—
—
—
—
—
—
—
—
—
cases:8.47%
controls:7.76%
cases:31.58%
controls:27.85%
—
—
—
—
—
5
46
54
547
18
161
39
417
Headache
R51.80 [2000503603]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
60
582
—
—
—
—
—
—
Other and unspecified abdominal pain
R10.4 [45568113]
—
—
—
—
—
—
3.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:6.57%
—
—
—
—
—
—
5
38
52
540
dexamethasone and antiinfectives
S01CA01 [21603652]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
60
586
—
—
—
—
—
—
Endomysium IgG Ab [Titer] in Serum
49726-3 [3032773]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
pH of Urine
2756-5 [3015736]
—
—
—
—
—
—
6.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.79%
controls:9.34%
—
—
—
—
—
—
9
54
48
524
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:1.52%
cases:0.00%
controls:2.77%
—
0
7
60
586
—
—
—
0
9
59
584
0
16
57
562
Abdominal pain/cramps general
D01 [2002000300]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
7
60
586
—
—
—
—
—
0
7
57
571
sildenafil; oral
G04BE03 [21602648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
Drugs identified in Urine by Screen method Nominal
12286-1 [3011288]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
0
9
57
569
Custom moulded cast, unspecified region
TNX33 [2001308564]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Tooth X-ray additional picture
EB1CA [2001301909]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Lipid panel - Serum or Plasma
100898-6 [1761868]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.52%
cases:0.00%
controls:2.02%
—
—
—
—
—
—
cases:0.00%
controls:2.36%
—
—
0
9
60
584
0
12
60
581
—
—
—
0
14
59
579
—
Opening and preparing the root canals, complicated
SGA03 [2001310381]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.81%
—
—
—
—
—
—
0
22
57
556
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-2.8e-01
6.9e-01
—
—
1.2e+00
4.4e-01
2.5e-01
cases:10.00%
controls:12.82%
cases:20.00%
controls:11.13%
—
—
—
—
cases:10.00%
controls:3.20%
cases:20.34%
controls:14.17%
cases:43.86%
controls:37.72%
6
76
54
517
12
66
48
527
—
—
6
19
54
574
12
84
47
509
25
218
32
360
C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
30522-7 [3010156]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Emergency use of U07.1 | COVID-19, virus identified
U07.1 [45756093]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.60%
—
—
—
—
—
—
0
15
57
563
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-2.8e-01
6.9e-01
—
—
1.2e+00
4.4e-01
2.5e-01
cases:10.00%
controls:12.82%
cases:20.00%
controls:11.13%
—
—
—
—
cases:10.00%
controls:3.20%
cases:20.34%
controls:14.17%
cases:43.86%
controls:37.72%
6
76
54
517
12
66
48
527
—
—
6
19
54
574
12
84
47
509
25
218
32
360
promethazine, combinations
R06AD52 [21603489]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
rosuvastatin; oral
C10AA07 [21601862]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
0
9
60
584
—
—
—
0
9
59
584
—
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
fusidic acid
S01AA13 [21603564]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
0
9
57
569
pH of Capillary blood
2745-8 [3009343]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
Intraoral radiographic dental examination
EB1AA [2001301903]
—
—
—
—
—
-1.0e+50
-4.8e-02
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.87%
cases:12.28%
controls:12.80%
—
—
—
—
—
0
17
59
576
7
74
50
504
Pediatric Gastroenterology
OMOP4822029 [45756810]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Acoustic neuroma
D33.30 [2000501332]
1.0e+50
—
—
—
—
—
1.0e+50
cases:10.00%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
cases:12.28%
controls:0.00%
6
0
54
593
—
—
—
—
—
7
0
50
578
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-5.0e-02
6.9e-01
—
—
1.3e+00
3.1e-01
1.9e-01
cases:10.00%
controls:10.46%
cases:16.67%
controls:9.11%
—
—
—
—
cases:8.33%
controls:2.36%
cases:15.25%
controls:11.64%
cases:35.09%
controls:30.97%
6
62
54
531
10
54
50
539
—
—
5
14
55
579
9
69
50
524
20
179
37
399
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
—
—
—
—
—
—
5.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:6.23%
—
—
—
—
—
—
6
36
51
542
follitropin beta; parenteral
G03GA06 [21602604]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Sexual health counselling
SPAT1308 [2001700409]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
60
584
—
—
—
—
—
—
Separate planning of oral and dental treatment, standard
SAC01 [2001310283]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:3.11%
—
—
—
—
—
—
5
18
52
560
ispaghula (psylla seeds); oral
A06AC01 [21600555]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
0
9
60
584
—
—
—
0
7
59
586
—
European house dust mite IgE Ab [Units/volume] in Serum
6096-2 [3023351]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Dental calculus supragingival
K03.64 [2000502689]
-1.0e+50
-1.0e+50
—
—
—
—
6.6e-01
cases:0.00%
controls:3.37%
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
cases:14.04%
controls:7.79%
0
20
60
573
0
6
60
587
—
—
—
—
8
45
49
533
diphenhydramine, combinations
R06AA52 [21603454]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
rivaroxaban; oral
B01AF01 [43534761]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
atorvastatin; oral
C10AA05 [21601860]
—
—
—
—
—
—
9.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:4.33%
—
—
—
—
—
—
6
25
51
553
Unspecified neurofibromatosis
Q85.09 [2000503518]
1.0e+50
1.0e+50
—
—
—
1.0e+50
1.0e+50
cases:16.67%
controls:0.00%
cases:16.67%
controls:0.00%
—
—
—
—
—
—
cases:15.25%
controls:0.00%
cases:22.81%
controls:0.00%
10
0
50
593
10
0
50
593
—
—
—
9
0
50
593
13
0
44
578
clopidogrel; oral
B01AC04 [21600989]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
Mouth breathing
R06.5 [45573006]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Basophils [#/volume] in Blood
26444-0 [3006315]
—
—
—
—
-1.0e+50
1.1e+00
5.2e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:8.47%
controls:3.04%
cases:15.79%
controls:10.03%
—
—
—
—
0
5
60
588
5
18
54
575
9
58
48
520
Adenotomy
EMB30 [2001302268]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
60
584
—
—
—
—
—
—
short-acting sulfonamides - combinations
J01EB20 [21602943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Maternal and Fetal Medicine
OMOP4821963 [45756780]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Metabolic syndrome
E66.00 [2000501500]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
—
—
—
—
—
5.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:6.40%
—
—
—
—
—
—
6
37
51
541
Colonoscopy Study observation
28023-0 [3022145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
0
10
57
568
Placement of prefabricated palatal or lingual arch
SJD40 [2001310441]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
Emergency Medicine
93 [38004510]
—
—
—
—
—
—
1.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:14.04%
controls:12.11%
—
—
—
—
—
—
8
70
49
508
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
cromoglicic acid
S01GX01 [21605085]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.28%
controls:3.11%
—
—
—
—
—
—
7
18
50
560
Otitis media, unspecified
H66.9 [45547965]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Exposure to unspecified factor
X59 [45756412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
60
585
—
—
—
—
—
—
Extraction of tooth
EBA00 [2001301923]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
0
8
60
585
—
—
—
0
6
59
587
—
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
levonorgestrel
G03AC03 [21602499]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.81%
0
14
60
579
—
—
—
—
—
0
22
57
556
Physical Medicine And Rehabilitation
25 [38004468]
—
—
—
—
—
—
2.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:7.27%
—
—
—
—
—
—
5
42
52
536
hydrocortisone
D07AA02 [21602102]
4.7e-01
—
—
—
—
—
4.6e-01
cases:11.67%
controls:7.59%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:5.71%
7
45
53
548
—
—
—
—
—
5
33
52
545
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:4.22%
cases:0.00%
controls:0.84%
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
0
25
60
568
0
5
60
588
—
—
—
0
9
59
584
—
sertraline; oral
N06AB06 [21604714]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
0
9
60
584
—
—
—
0
8
59
585
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
—
7.7e-01
-1.0e+50
—
-1.0e+50
9.7e-01
3.7e-01
—
—
cases:8.33%
controls:4.05%
cases:0.00%
controls:0.84%
—
—
cases:0.00%
controls:1.01%
cases:8.47%
controls:3.37%
cases:15.79%
controls:11.42%
—
5
24
55
569
0
5
60
588
—
0
6
60
587
5
20
54
573
9
66
48
512
insulin (beef); parenteral
A10AD02 [21600730]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
0
7
60
586
—
—
—
—
Lump/swelling localized
S04 [2002000969]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Therapeutic intervention or check-up related to orthodontic treatment
SJX21 [2001310455]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Biopsy of vaginal cervix
LDA20 [2001306656]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
Genetic counselling
Z31.5 [45590715]
—
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:0.00%
cases:22.81%
controls:0.00%
—
—
—
—
—
6
0
53
593
13
0
44
578
enalapril; oral, parenteral
C09AA02 [21601786]
1.9e+00
—
—
—
—
—
—
cases:8.33%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
5
8
55
585
—
—
—
—
—
—
pregabalin; oral
N02BF02 [955152]
1.1e+00
—
—
—
—
—
1.4e+00
cases:8.33%
controls:2.87%
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:2.94%
5
17
55
576
—
—
—
—
—
6
17
51
561
Routine postpartum follow-up
Z39.2 [45547306]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
0
5
60
588
—
—
—
—
—
0
8
57
570
Functional diarrhoea
K59.1 [45543327]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
Medical abortion, complete or unspecified, without complication
O04.9 [45543909]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
azelaic acid; ointment
D10AX03 [21602314]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
5
60
588
—
—
—
—
—
0
7
57
571
tolfenamic acid; oral, rectal
M01AG02 [21603988]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
0
9
57
569
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.63%
—
—
—
—
—
—
0
21
57
557
Simple examination of mouth
SAA01 [2001310274]
-2.9e-01
6.7e-01
—
—
—
—
-1.8e-01
cases:10.00%
controls:12.98%
cases:10.00%
controls:5.40%
—
—
—
—
—
—
—
—
cases:21.05%
controls:24.22%
6
77
54
516
6
32
54
561
—
—
—
—
12
140
45
438
metronidazole; oral, rectal
P01AB01 [21604857]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:4.33%
—
—
—
—
—
—
5
25
52
553
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
Fever, unspecified
R50.9 [45582716]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
—
0
10
60
583
—
—
—
—
—
insulin (human); parenteral
A10AB01 [21600715]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
0
10
60
583
—
—
Anxiety disorder/anxiety state
P74 [2002000868]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
doxycycline; oral, parenteral
J01AA02 [21602800]
1.8e-01
—
—
—
—
-1.0e+50
5.4e-01
cases:16.67%
controls:14.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.88%
cases:21.05%
controls:13.49%
10
85
50
508
—
—
—
—
0
23
59
570
12
78
45
500
Presence of intraocular lens
Z96.1 [45585885]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
6
60
587
—
—
—
—
—
0
5
57
573
drospirenone and ethinylestradiol
G03AA12 [21602485]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Spinal stenosis
M48.0 [45557888]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Person encountering health services in unspecified circumstances
Z76.9 [45609967]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
0
9
57
569
Obstetrics / Gynecology
16 [38004461]
-1.5e-01
—
—
—
—
3.3e-01
7.4e-01
cases:11.67%
controls:13.32%
—
—
—
—
—
—
—
—
cases:8.47%
controls:6.24%
cases:26.32%
controls:14.53%
7
79
53
514
—
—
—
—
5
37
54
556
15
84
42
494
ebastine; oral
R06AX22 [21603521]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.02%
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.94%
0
12
60
581
0
8
60
585
—
—
—
—
0
17
57
561
Examination for adolescent development state
Z00.3 [45580999]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
0
9
57
569
Neck symptom/complaint
L01 [2002000626]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.08%
—
—
—
—
—
—
0
12
57
566
nystatin; oral
A07AA02 [21600604]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
aciclovir; oral, parenteral
J05AB01 [21603131]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.29%
—
—
—
—
—
—
0
19
57
559
nimesulide; oral
M01AX17 [21604007]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
6
60
587
—
—
—
—
—
0
5
57
573
chloramphenicol; ointment
D06AX02 [21602063]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-2.8e-01
6.9e-01
—
—
1.2e+00
4.4e-01
2.5e-01
cases:10.00%
controls:12.82%
cases:20.00%
controls:11.13%
—
—
—
—
cases:10.00%
controls:3.20%
cases:20.34%
controls:14.17%
cases:43.86%
controls:37.72%
6
76
54
517
12
66
48
527
—
—
6
19
54
574
12
84
47
509
25
218
32
360
Screening procedure
SPAT1324 [2001700425]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.69%
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:2.19%
—
—
0
10
60
583
0
9
60
584
—
—
—
0
13
59
580
—
candesartan; oral
C09CA06 [21601829]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
0
5
60
588
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
—
—
—
—
—
-1.0e+50
7.5e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
cases:8.77%
controls:4.33%
—
—
—
—
—
0
6
59
587
5
25
52
553
Fitting of removable appliance incl. patient instructions
SJB00 [2001310422]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Intravenous
ZX120 [2001311495]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
5
60
588
—
—
—
—
—
0
7
57
571
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
—
8.4e-01
—
—
1.5e+00
3.7e-01
3.5e-01
—
—
cases:16.67%
controls:7.93%
—
—
—
—
cases:8.33%
controls:2.02%
cases:13.56%
controls:9.78%
cases:33.33%
controls:26.12%
—
10
47
50
546
—
—
5
12
55
581
8
58
51
535
19
151
38
427
Centromere protein B Ab [Units/volume] in Serum
53982-5 [3039162]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
clobetasol
D07AD01 [21602141]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
Demanding placement of orthodontic arch wire
SJD30 [2001310440]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
—
—
—
—
—
—
5.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:6.23%
—
—
—
—
—
—
6
36
51
542
dexamethasone
D07AB19 [21602116]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Treatment plan or consultation
WZC00 [2001310885]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:5.19%
—
—
—
—
—
—
5
30
52
548
Foot/toe symptom/complaint
L17 [2002000641]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
0
7
59
586
—
Low back pain
M54.5 [45553207]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
—
0
10
60
583
—
—
—
—
—
hydrocortisone; local oral
A01AC03 [21600036]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.5e-02
1.2e-01
—
—
—
2.4e-01
4.6e-01
cases:10.00%
controls:9.78%
cases:10.00%
controls:8.94%
—
—
—
—
—
—
cases:13.56%
controls:10.96%
cases:40.35%
controls:29.93%
6
58
54
535
6
53
54
540
—
—
—
8
65
51
528
23
173
34
405
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
7
60
586
—
—
—
—
—
Nonallergic asthma
J45.1 [45557625]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:1.21%
0
9
60
584
—
—
—
—
0
7
59
586
0
7
57
571
amoxicillin; oral, parenteral
J01CA04 [21602823]
5.4e-01
—
-1.0e+50
—
—
8.2e-02
3.7e-01
cases:41.67%
controls:29.34%
—
—
cases:0.00%
controls:1.18%
—
—
—
—
cases:10.17%
controls:9.44%
cases:31.58%
controls:24.22%
25
174
35
419
—
0
7
60
586
—
—
6
56
53
537
18
140
39
438
clonazepam; oral, parenteral
N03AE01 [21604415]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:1.21%
—
—
—
—
—
0
5
59
588
0
7
57
571
Other blockage of nerve
WX290 [2001310792]
—
-1.0e+50
—
—
—
-1.0e+50
3.8e-01
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:3.54%
cases:14.04%
controls:10.03%
—
0
9
60
584
—
—
—
0
21
59
572
8
58
49
520
Hypertrophy of adenoids
J35.2 [45552887]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Tympanometry
SPAT1044 [2001700145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
Rash localized
S06 [2002000971]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
phenoxymethylpenicillin; oral
J01CE02 [21602842]
2.8e-01
—
—
—
—
—
-4.5e-01
cases:23.33%
controls:18.72%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:13.15%
14
111
46
482
—
—
—
—
—
5
76
52
502
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
0
9
60
584
—
—
—
0
8
59
585
—
sulfadiazine and trimethoprim
J01EE02 [21602962]
4.7e-01
-1.0e+50
—
—
—
—
—
cases:8.33%
controls:5.40%
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
5
32
55
561
0
5
60
588
—
—
—
—
—
Acute upper respiratory infection, unspecified
J06.9 [45562437]
—
—
—
—
—
-1.0e+50
-2.0e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.53%
cases:8.77%
controls:10.55%
—
—
—
—
—
0
15
59
578
5
61
52
517
prednisone
A07EA03 [21600655]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
Fracture of lower end of radius
S52.5 [45573842]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
dexchlorpheniramine, combinations
R06AB52 [21603467]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
60
578
—
—
—
—
—
—
One hour or less
ZXE00 [2001311394]
3.4e-01
—
—
—
—
—
8.9e-01
cases:8.33%
controls:6.07%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:3.81%
5
36
55
557
—
—
—
—
—
5
22
52
556
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
codeine and paracetamol
N02AJ06 [1123647]
—
—
-1.0e+50
—
-1.0e+50
—
4.2e-01
—
—
—
—
cases:0.00%
controls:0.84%
—
—
cases:0.00%
controls:1.18%
—
—
cases:17.54%
controls:12.28%
—
—
0
5
60
588
—
0
7
60
586
—
10
71
47
507
Extensive health check-up of children and adolescents
SPAT1316 [2001700417]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.29%
—
0
5
60
588
—
—
—
—
0
19
57
559
Care involving use of rehabilitation procedure, unspecified
Z50.9 [45595525]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Administration of medicine
SPAT1254 [2001700355]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
0
7
60
586
0
6
60
587
—
—
—
—
—
Gynecological ultrasound examination as part of clinical examination
LX1AE [2001306815]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
prednisolone; oral, parenteral
H02AB06 [21602734]
4.3e-01
—
—
—
—
—
2.8e-01
cases:10.00%
controls:6.75%
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:8.13%
6
40
54
553
—
—
—
—
—
6
47
51
531
Free T4 and TSH panel - Serum or Plasma
24348-5 [3001019]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
oxazepam; oral
N05BA04 [21604569]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:3.29%
—
—
—
—
—
—
5
19
52
559
Atrial fibrillation and flutter
I48 [45596206]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
0
9
57
569
Assessment of need for oral health care, standard
SAD01 [2001310287]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
60
584
—
—
—
—
—
—
Ultrasound examination of mammary glands
HA1AE [2001303886]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
tetracycline; oral, parenteral
J01AA07 [21602805]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
0
9
57
569
Examination of postural anomaly
SPAT1213 [2001700314]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
0
6
60
587
—
—
—
—
—
0
6
57
572
amlodipine; oral
C08CA01 [21601747]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:2.53%
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
0
15
60
578
—
—
0
7
60
586
—
—
Coeliac disease
K90.0 [45586745]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
amitriptyline; oral, parenteral
N06AA09 [21604696]
—
—
—
—
—
—
9.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:3.46%
—
—
—
—
—
—
5
20
52
558
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:0.84%
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
0
5
60
588
0
5
60
588
—
—
—
0
8
59
585
—
folic acid; oral, parenteral
B03BB01 [21601129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
rubella, live attenuated
J07BJ01 [21601359]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
—
—
—
—
-1.0e+50
1.1e+00
4.3e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:8.47%
controls:3.04%
cases:15.79%
controls:10.90%
—
—
—
—
0
5
60
588
5
18
54
575
9
63
48
515
General anesthesia, balanced
WX408 [2001310808]
8.4e-01
—
—
—
—
—
1.5e+00
cases:10.00%
controls:4.55%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:2.08%
6
27
54
566
—
—
—
—
—
5
12
52
566
Acute maxillary sinusitis
J01.0 [45601112]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
0
10
59
583
—
Knee symptom/complaint
L15 [2002000639]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.85%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
0
11
60
582
—
—
—
—
0
5
59
588
—
fluticasone furoate; nasal
R01AD12 [21605053]
4.7e-01
—
—
—
—
—
—
cases:11.67%
controls:7.59%
—
—
—
—
—
—
—
—
—
—
—
—
7
45
53
548
—
—
—
—
—
—
montelukast; oral
R03DC03 [21603356]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:2.02%
—
—
—
0
9
60
584
—
—
—
0
12
59
581
—
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
—
—
—
—
—
—
6.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:4.84%
—
—
—
—
—
—
5
28
52
550
Gynaecological examination
SPAT1192 [2001700293]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
epinephrine
S01EA01 [21603673]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
60
585
—
—
—
—
—
—
Impacted cerumen
H61.2 [45562307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
desonide
D07AB08 [21602112]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.90%
0
7
60
586
—
—
—
—
—
0
11
57
567
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
—
5.8e-01
—
—
1.3e+00
8.7e-01
4.6e-01
—
—
cases:13.33%
controls:7.93%
—
—
—
—
cases:8.33%
controls:2.36%
cases:18.64%
controls:8.77%
cases:35.09%
controls:25.43%
—
8
47
52
546
—
—
5
14
55
579
11
52
48
541
20
147
37
431
losartan; oral
C09CA01 [21601824]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.28%
controls:2.94%
—
—
—
—
—
—
7
17
50
561
isotretinoin; oral
D10BA01 [21602320]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
6
60
587
—
—
—
—
—
0
7
57
571
Pain in joint
M25.5 [45586941]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
0
6
59
587
—
scopolamine; oral, parenteral
N05CM05 [21604666]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
plastic IUD with progestogen; implant
G02BA03 [21602449]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
60
577
—
—
—
—
—
—
General Practice
1 [38004446]
5.0e-01
—
—
—
—
1.1e+00
8.1e-01
cases:11.67%
controls:7.42%
—
—
—
—
—
—
—
—
cases:8.47%
controls:3.04%
cases:17.54%
controls:8.65%
7
44
53
549
—
—
—
—
5
18
54
575
10
50
47
528
Toothache NOS
K08.80 [2000502799]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
0
9
57
569
Operative extraction of tooth
EBA10 [2001301925]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
60
582
—
—
—
—
—
—
Bloodpressure measurement
XF600 [2001303376]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
5
60
588
—
—
—
—
—
0
5
57
573
Diarrhoea
D11 [2002000310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
—
—
—
—
—
—
7.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:14.04%
controls:7.27%
—
—
—
—
—
—
8
42
49
536
Otalgia
H92.0 [45596177]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
8
57
570
cefaclor; oral
J01DC04 [21602886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
60
580
—
—
—
—
—
—
Preventive oral health care, short
SCA01 [2001310302]
—
—
—
—
—
-1.0e+50
-1.1e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.70%
cases:8.77%
controls:9.69%
—
—
—
—
—
0
16
59
577
5
56
52
522
hydrocortisone
A07EA02 [21600654]
4.5e-01
—
—
—
—
—
4.3e-01
cases:11.67%
controls:7.76%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:5.88%
7
46
53
547
—
—
—
—
—
5
34
52
544
Venereal disease screening
171128005 [4064905]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Fissure sealant
SCE00 [2001310316]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
salmeterol; inhalant
R03AC12 [21603266]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
hydrocortisone butyrate
D07AB02 [21602106]
4.7e-01
—
—
—
—
—
4.6e-01
cases:11.67%
controls:7.59%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:5.71%
7
45
53
548
—
—
—
—
—
5
33
52
545
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-1.2e-01
8.4e-01
—
—
1.7e+00
5.3e-01
4.8e-01
cases:8.33%
controls:9.27%
cases:13.33%
controls:6.24%
—
—
—
—
cases:8.33%
controls:1.69%
cases:15.25%
controls:9.61%
cases:36.84%
controls:26.47%
5
55
55
538
8
37
52
556
—
—
5
10
55
583
9
57
50
536
21
153
36
425
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
60
585
—
—
—
—
—
—
Nephrology
39 [38004479]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:10.17%
controls:0.00%
—
—
—
—
—
—
—
6
0
53
593
—
Tooth plaque
K03.66 [2000502691]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
0
10
57
568
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
0
7
59
586
—
Other allergic rhinitis
J30.3 [45538477]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Treatment of a patient needing special arrangements
WYA30 [2001310874]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Extensive health check-up on fifth grade
SPAT1385 [2001700485]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
0
5
59
588
—
combinations of corticosteroids
D07AB30 [21602118]
2.0e-01
—
—
—
—
—
7.0e-01
cases:11.67%
controls:9.78%
—
—
—
—
—
—
—
—
—
—
cases:15.79%
controls:8.48%
7
58
53
535
—
—
—
—
—
9
49
48
529
Stomach Pathology biopsy report
66114-0 [40768797]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
norfloxacin; oral
J01MA06 [21603013]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
loperamide oxide; oral
A07DA05 [21600648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Supplier / Service Provider
OMOP5117446 [33004]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
0
8
60
585
—
—
—
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
3.4e-01
9.7e-04
—
—
—
2.3e-01
1.6e-01
cases:35.00%
controls:27.66%
cases:13.33%
controls:13.32%
—
—
—
—
—
—
cases:16.95%
controls:14.00%
cases:38.60%
controls:34.95%
21
164
39
429
8
79
52
514
—
—
—
10
83
49
510
22
202
35
376
Dental impressions
SBB10 [2001310299]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.25%
—
—
—
—
—
—
0
13
57
565
telithromycin; oral
J01FA15 [21602983]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
60
585
—
—
—
—
—
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
—
—
—
—
—
—
2.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:21.05%
controls:16.96%
—
—
—
—
—
—
12
98
45
480
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.08%
—
—
—
—
—
—
0
12
57
566
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Streptococcal tonsillitis
J03.0 [45601114]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-3.1e-02
8.9e-01
—
—
1.5e+00
7.6e-01
2.9e-01
cases:10.00%
controls:10.29%
cases:18.33%
controls:8.43%
—
—
—
—
cases:10.00%
controls:2.53%
cases:20.34%
controls:10.62%
cases:36.84%
controls:30.45%
6
61
54
532
11
50
49
543
—
—
6
15
54
578
12
63
47
530
21
176
36
402
fluorometholone
S01BA07 [21603624]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
-1.0e+50
—
—
—
—
6.3e-01
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
cases:10.53%
controls:5.88%
—
0
7
60
586
—
—
—
—
6
34
51
544
Stomatognathic treatment, basic
SHA02 [2001310406]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Laser discission of secondary cataract
CJB10 [2001301313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Weakness/tiredness general
A04 [2002000145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
Complicated extraction of tooth
EBA05 [2001301924]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:2.42%
—
—
—
—
—
0
7
59
586
0
14
57
564
Periodontal treatment, brief
SDA02 [2001310327]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
0
8
60
585
—
—
—
—
—
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:14.04%
controls:3.63%
—
—
—
—
—
—
8
21
49
557
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
—
—
—
—
—
—
4.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:28.07%
controls:20.76%
—
—
—
—
—
—
16
120
41
458
Laboratory Visit
OMOP4822461 [32036]
-5.3e-02
3.0e-01
3.1e-01
—
7.1e-01
1.8e-01
2.0e-01
cases:15.00%
controls:15.68%
cases:21.67%
controls:17.03%
cases:8.33%
controls:6.24%
—
—
cases:11.67%
controls:6.07%
cases:23.73%
controls:20.57%
cases:49.12%
controls:44.12%
9
93
51
500
13
101
47
492
5
37
55
556
—
7
36
53
557
14
122
45
471
28
255
29
323
Fear sexually transm disease male
Y25 [2002001393]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Supervision of other normal pregnancy
Z34.8 [45537628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
dexbrompheniramine, combinations
R06AB56 [21603469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
5
57
573
Monitoring of emergency patient
SPAT1104 [2001700205]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
6
57
572
medroxyprogesterone and estradiol
G03AA17 [715900]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—
Platelets [#/volume] in Blood
26515-7 [3007461]
-2.5e-01
7.1e-01
—
—
1.3e+00
4.5e-01
2.5e-01
cases:10.00%
controls:12.48%
cases:20.00%
controls:10.96%
—
—
—
—
cases:10.00%
controls:3.04%
cases:20.34%
controls:14.00%
cases:43.86%
controls:37.72%
6
74
54
519
12
65
48
528
—
—
6
18
54
575
12
83
47
510
25
218
32
360
bisoprolol; oral
C07AB07 [21601689]
—
—
—
—
—
—
5.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.28%
controls:7.79%
—
—
—
—
—
—
7
45
50
533
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
—
—
-1.0e+50
—
-1.0e+50
1.0e+00
5.4e-01
—
—
—
—
cases:0.00%
controls:0.84%
—
—
cases:0.00%
controls:1.01%
cases:8.47%
controls:3.20%
cases:15.79%
controls:9.86%
—
—
0
5
60
588
—
0
6
60
587
5
19
54
574
9
57
48
521
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:2.36%
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
0
14
60
579
—
—
—
0
9
59
584
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
6.0e-01
—
—
—
—
—
9.3e-01
cases:10.00%
controls:5.73%
—
—
—
—
—
—
—
—
—
—
cases:14.04%
controls:6.06%
6
34
54
559
—
—
—
—
—
8
35
49
543
erythromycin; oral, parenteral
J01FA01 [21602970]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
60
586
—
—
—
—
—
—
Audiology
64 [38004489]
1.5e+00
—
—
—
—
—
—
cases:8.33%
controls:2.02%
—
—
—
—
—
—
—
—
—
—
—
—
5
12
55
581
—
—
—
—
—
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Oral health check
SAB03 [2001310281]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
0
5
60
588
—
—
—
—
0
7
59
586
—
pivmecillinam; oral
J01CA08 [21602827]
3.3e-01
—
—
—
—
—
3.1e-01
cases:10.00%
controls:7.42%
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:7.96%
6
44
54
549
—
—
—
—
—
6
46
51
532
betamethasone
S02BA07 [21605169]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
7
60
586
—
—
—
—
—
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
—
—
—
—
-1.0e+50
1.1e+00
7.3e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:8.47%
controls:2.87%
cases:15.79%
controls:8.30%
—
—
—
—
0
5
60
588
5
17
54
576
9
48
48
530
Radiological examination, not elsewhere classified
Z01.6 [45605096]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
60
588
—
—
—
—
—
—
Pure hypercholesterolaemia
E78.01 [2000501514]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
7
60
586
—
—
—
—
—
celecoxib
L01XX33 [21603805]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
0
10
57
568
hydrocortisone aceponate
D07AC16 [21602135]
4.7e-01
—
—
—
—
—
4.6e-01
cases:11.67%
controls:7.59%
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:5.71%
7
45
53
548
—
—
—
—
—
5
33
52
545
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
7
57
571
One-surface restoration
SFA10 [2001310358]
-5.6e-02
-1.0e+50
—
—
—
—
-2.5e-01
cases:8.33%
controls:8.77%
cases:0.00%
controls:3.37%
—
—
—
—
—
—
—
—
cases:10.53%
controls:13.15%
5
52
55
541
0
20
60
573
—
—
—
—
6
76
51
502
Short blood count panel - Blood
55429-5 [40758558]
—
—
—
—
—
—
8.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.77%
controls:4.15%
—
—
—
—
—
—
5
24
52
554
Arthritis, unspecified
M13.9 [45567463]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
60
587
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
10
6
18.91
6.96
6.2
3.2
1.95
2.30
nmol/l
—
10
6
17
42
4.94
6.78
1.2
1.7
—
—
—
0
0
23
76
3.92
6.31
1.4
1.2
—
—
—
0
0
22
73
3.85
5.98
7.3
20.2
23.29
25.00
mmol/l
2.08
22
73
16
46
4.15
5.23
7.6
11.9
0.14
1.71
mmol/l
0.92
11
40
34
160
3.06
5.23
5.9
4.6
7.39
7.40
ph
0.69
29
110
16
47
4.06
5.08
7.6
11.8
7.40
7.43
ph
—
9
30
37
187
2.93
4.95
4.9
3.6
—
—
estimate
—
0
0
8
7
12.59
4.91
1.8
1.6
—
—
nmol/l
—
0
0
23
90
3.24
4.78
2.5
11.2
29.43
30.17
s
0.26
23
90
9
12
8.34
4.50
2.3
5.8
7.42
7.41
ph
—
9
12
24
106
2.86
3.99
4.6
3.4
2.29
2.27
e6/l
0.00
16
53
8
11
7.98
3.97
2.3
1.6
0.56
0.46
nmol/l
—
8
11
6
5
12.87
3.83
6.3
2.6
138.83
346.20
nmol/l
—
6
5
20
85
2.84
3.53
3.1
11.9
0.81
0.80
mmol/l
0.05
20
80
49
338
2.30
2.91
6.3
7.3
6.12
6.24
mmol/l
0.18
49
314
30
169
2.29
2.91
2.8
3.7
13.28
42.54
ng/l
1.13
18
100
44
292
2.23
2.85
4.4
3.4
6.74
6.30
ph
1.17
19
148
25
131
2.36
2.85
4.2
4.8
—
—
—
0
0
58
433
2.50
2.82
5.3
4.4
—
—
—
0
0
37
230
2.20
2.81
1.9
1.8
—
—
—
0
0
6
10
6.41
2.75
2.0
6.1
4.50
5.15
kpa
—
6
10
6
10
6.41
2.75
2.0
6.1
9.55
9.97
kpa
—
6
10
18
83
2.54
2.67
7.1
13.1
—
—
—
0
0
6
11
5.82
2.59
1.8
3.0
1.58
1.57
mmol/l
—
6
11
8
21
4.13
2.54
5.0
5.0
—
—
—
0
0
48
340
2.14
2.52
4.8
3.9
0.00
0.00
estimate
-0.00
12
69
32
195
2.12
2.49
2.8
3.2
—
—
—
0
0
48
341
2.13
2.49
4.9
3.9
0.00
0.00
estimate
-0.00
11
69
6
12
5.33
2.45
1.7
3.8
17.95
16.48
%
—
6
12
45
318
2.04
2.30
14.0
15.4
0.00
0.00
e9/l
0.25
38
256
9
30
3.27
2.23
10.7
15.7
94.46
95.26
%
—
9
30
8
182
0.37
2.22
3.4
1.8
—
—
—
0
0
48
350
2.03
2.22
4.9
3.9
0.00
0.00
estimate
-0.00
12
62
0
55
0.00
2.17
0.0
1.0
—
—
—
0
0
9
32
3.05
2.08
10.7
14.8
0.99
1.09
%
—
9
32
9
32
3.05
2.08
10.7
14.7
0.50
0.60
%
—
9
32
5
11
4.78
1.97
2.4
3.7
3.69
4.46
e9/l
—
5
11
5
11
4.78
1.97
1.8
7.6
—
—
—
0
0
15
74
2.28
1.91
1.6
2.1
—
—
—
0
0
67
577
2.51
1.91
20.3
19.2
13.35
13.21
%
0.37
67
572
6
17
3.74
1.88
2.2
3.1
60.50
57.56
%
—
6
17
5
12
4.38
1.85
1.6
6.8
—
—
—
0
0
5
12
4.38
1.85
2.0
3.6
93.38
90.65
%
—
5
12
34
232
1.85
1.80
7.4
12.5
—
—
—
0
0
8
30
2.86
1.78
10.1
14.3
24.00
25.15
mmol/l
—
8
30
39
280
1.82
1.74
3.1
3.4
—
—
estimate
—
0
0
27
173
1.88
1.73
5.6
3.8
—
—
—
0
0
70
622
2.88
1.70
25.2
15.3
4.00
3.92
mmol/l
1.63
70
609
70
622
2.88
1.70
25.9
15.3
139.01
139.67
mmol/l
0.89
70
610
6
20
3.17
1.61
1.5
5.9
—
—
—
0
0
25
162
1.81
1.52
3.3
2.7
—
—
—
0
0
6
22
2.87
1.46
5.7
7.0
36.97
36.94
°c
—
6
22
6
22
2.87
1.46
3.0
2.9
22.30
25.11
mmol/l
—
6
22
6
126
0.43
1.32
1.3
1.3
—
29.79
—
0
38
7
137
0.46
1.26
3.9
1.6
—
—
—
0
0
15
234
0.55
1.22
2.5
2.2
—
—
—
0
0
25
173
1.67
1.19
4.4
4.2
0.00
0.00
estimate
-0.00
12
65
22
150
1.66
1.09
2.3
3.1
—
—
—
0
0
12
68
1.91
1.08
6.2
8.9
7.40
7.41
ph
0.32
12
56
29
214
1.58
1.05
4.6
10.5
—
—
—
0
0
10
54
1.98
1.02
4.9
4.1
—
—
—
0
0
0
28
0.00
1.00
0.0
1.6
—
—
—
0
0
12
70
1.85
0.99
1.2
1.6
—
—
—
0
0
12
72
1.79
0.91
10.5
12.6
106.33
104.29
mmol/l
0.37
12
72
27
203
1.52
0.88
2.1
1.7
93.21
100.12
pmol/l
0.34
14
95
47
397
1.49
0.87
10.3
14.8
3.99
3.74
e9/l
0.30
42
346
6
33
1.89
0.81
1.5
1.2
—
—
—
0
0
9
143
0.58
0.80
1.3
1.9
—
—
—
0
0
44
371
1.45
0.79
7.0
11.8
0.20
0.18
e9/l
0.21
38
320
24
181
1.48
0.76
3.2
3.3
0.00
0.00
estimate
-0.00
11
58
9
57
1.66
0.74
6.4
8.8
—
—
—
0
0
42
356
1.41
0.70
7.2
11.4
0.59
0.54
e9/l
0.72
37
305
42
358
1.39
0.67
7.2
11.4
0.04
0.04
e9/l
0.32
37
307
8
49
1.71
0.64
1.1
2.2
—
314.15
u/l
—
0
13
30
244
1.38
0.62
4.3
3.6
0.00
0.02
estimate
—
10
62
0
22
0.00
0.60
0.0
1.4
—
—
—
0
0
0
22
0.00
0.60
0.0
1.5
—
—
—
0
0
6
35
1.77
0.59
1.0
1.1
—
—
—
0
0
42
366
1.34
0.54
7.2
11.2
1.77
2.05
e9/l
1.19
37
322
6
40
1.54
0.53
1.0
1.1
—
—
—
0
0
10
69
1.52
0.47
4.8
2.6
—
—
—
0
0
10
69
1.52
0.47
3.4
2.7
2.51
2.42
mmol/l
—
10
63
10
70
1.49
0.44
4.9
12.7
23.82
23.74
mmol/l
—
10
70
5
31
1.66
0.44
1.0
1.2
—
—
—
0
0
38
334
1.28
0.43
6.9
10.9
56.23
53.71
%
0.66
38
327
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
8.54
—
0
10
0
16
0.00
0.41
0.0
17.4
—
60.03
—
0
16
11
80
1.44
0.41
1.9
4.6
11.80
235.89
ng/l
—
5
47
0
18
0.00
0.40
0.0
15.9
—
62.14
—
0
18
10
74
1.41
0.34
1.6
1.5
—
—
—
0
0
7
55
1.30
0.31
8.7
9.7
23.53
24.15
mmol/l
—
7
55
25
218
1.22
0.28
1.4
1.6
—
—
—
0
0
5
37
1.38
0.24
19.0
6.0
7.38
7.34
ph
—
5
26
7
90
0.76
0.24
1.4
1.6
—
—
—
0
0
5
42
1.20
0.22
3.4
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
1182.83
—
0
6
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
0.51
—
0
7
0
12
0.00
0.21
0.0
22.6
—
9.85
—
0
12
0
12
0.00
0.21
0.0
6.1
—
0.33
—
0
7
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
29
263
1.17
0.21
1.7
1.8
1.44
1.31
mmol/l
0.28
23
234
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
4.40
—
0
8
7
62
1.14
0.18
1.0
1.4
—
—
—
0
0
7
62
1.14
0.18
1.0
1.4
138.69
104.84
u/ml
—
7
57
22
243
0.87
0.17
4.1
2.5
—
—
—
0
0
6
75
0.78
0.16
4.0
1.4
—
—
—
0
0
18
165
1.12
0.10
1.4
1.7
—
—
—
0
0
21
224
0.91
0.08
1.5
1.7
1.58
1.89
g/l
0.61
11
133
7
80
0.86
0.07
4.7
1.4
—
—
—
0
0
7
80
0.86
0.07
4.4
1.4
—
—
—
0
0
17
160
1.08
0.04
4.4
7.1
—
—
—
0
0
10
94
1.07
0.01
1.1
1.2
—
—
—
0
0
15
156
0.95
0.00
4.9
3.6
1.02
1.02
kg/l
—
9
97
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
12.0
—
0.65
—
0
5
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
6.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
4.13
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
0.86
—
0
7
0
5
0.00
-0.00
0.0
19.4
—
0.60
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
6.40
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
9.58
—
0
5
0
5
0.00
-0.00
0.0
8.8
—
12.20
—
0
5
0
5
0.00
-0.00
0.0
4.4
—
34.00
—
0
5
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
10.14
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
83.51
—
0
5
7
78
0.89
-0.00
4.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
6.55
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
0.32
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
7
78
0.89
-0.00
4.4
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.3
—
31.78
—
0
9
0
8
0.00
-0.00
0.0
1.9
—
5.51
—
0
8

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: Q17_TUBEROUS_SCLEROSIS – Tuberous sclerosis 1

GWS hits: 1

This endpoint is excluded (different definition than used in FinnGen).